Cascades Reports Results for the First Quarter of 2026

PR Newswire
Today at 10:00am UTC

Cascades Reports Results for the First Quarter of 2026

PR Newswire

KINGSEY FALLS, QC, May 7, 2026 /PRNewswire/ - Cascades Inc. (TSX: CAS) reports its unaudited financial results for the three-month period ended March 31, 2026.

Q1 2026 Highlights

  • Sales of $1,125 million (compared with $1,197 million in Q4 2025 and $1,154 million in Q1 2025);
  • Operating income of $81 million (compared with $76 million in Q4 2025 and $50 million in Q1 2025);
  • Net earnings per common share of $0.38 (compared with $0.37 in Q4 2025 and $0.07 in Q1 2025);
  • Adjusted earnings before interest, taxes, depreciation and amortization (EBITDA (A)1) of $118 million (compared with $155 million in Q4 2025 and $125 million in Q1 2025);
  • Adjusted net earnings per common share1 of $0.07 (compared with $0.40 in Q4 2025 and $0.13 in Q1 2025);
  • Net debt1 of $1,901 million as of March 31, 2026 (compared with $1,896 million as of December 31, 2025). Net debt to EBITDA (A) ratio1 remained stable at 3.3x;
  • Total capital expenditures of $28 million in Q1 2026, compared to $42 million in Q4 2025 and $36 million in Q1 2025. The Corporation's 2026 forecasted capital expenditures before disposals will be in a range of $150 million to $175 million.
  • The Company generated $91 million in asset sale proceeds during the first quarter, bringing total proceeds to $149 million for the 2025 - 2026 period. The Company's objective of generating $230 million is progressing well and is expected to be achieved by the end of third quarter of 2026.

Hugues Simon, President and CEO, commented: "First quarter results came in below our initial forecast, reflecting equally weighted external and operational factors. As disclosed in our revised outlook on April 10, weather‑related disruptions across the U.S., combined with heightened volatility in transportation and fuel costs, drove operating costs above plan. Additionally, recent geopolitical developments weighed on consumer confidence and spending, resulting in packaging volumes below our original assumptions. Performance was further impacted by temporary execution inefficiencies in the second half of the quarter. Despite this, net debt remained stable sequentially, and the leverage ratio was unchanged at 3.3x."

Discussing near-term outlook, Mr. Simon commented, "We expect results in the second quarter to be modestly lower sequentially. This outlook reflects a cautious packaging volume outlook amid restrained consumer spending levels, as well as continued volatility and upward pressure on input costs. The implementation of announced price increases in both segments is expected to fully offset these headwinds, with pricing actions taking effect in packaging beginning in the second quarter and during the second half of the year in tissue.

Amid the dynamic macro-economic environment we have strengthened our execution discipline to achieve our objective of generating $100 million of profitability improvements by the end of 2026. Key drivers include ongoing cost reduction initiatives, logistics optimization, productivity efficiency enhancements and targeted pricing actions to mitigate significant cost headwinds. We expect to achieve our target of proceeds from the sale of non-core assets by the end of the third quarter, and continue to actively review our portfolio of assets to ensure strong alignment with the Company's long-term strategic objectives. Given persistent cost pressures in the first half of 2026, annual results are currently expected to be below 2025 levels; however countermeasures, including selling price initiatives, that are currently underway are projected to restore annual run rate adjusted EBITDA (A)1 to a level of approximately $600 million in the second half of the year. In this context, achieving our targeted leverage ratio of 2.5x-3.0x by year-end may be challenging, though the target remains unchanged."

1 Some information represents non-IFRS Accounting Standards Financial measures, other financial measures or non-IFRS Accounting Standards ratios which are not standardized under IFRS Accounting Standards and therefore might not be comparable to similar financial measures disclosed by other corporations. Please refer to the "Supplemental Information on Non-IFRS Accounting Standards Measures and Other Financial Measures" section for a complete reconciliation.

Financial Summary

Selected consolidated information

(in millions of Canadian dollars, except amounts per common share) (unaudited)  

Q1 2026

Q4 2025

Q1 2025





Sales

1,125

1,197

1,154

As Reported




Operating income

81

76

50

Net earnings

39

37

7

per common share (basic)

$0.38

$0.37

$0.07

Adjusted1




Earnings before interest, taxes, depreciation and amortization (EBITDA (A))

118

155

125

Net earnings

7

40

13

per common share (basic)

$0.07

$0.40

$0.13

Margin (EBITDA (A) / Sales)

10.5 %

12.9 %

10.8 %

Net debt1

1,901

1,896

2,216

Net debt / EBITDA (A) ratio1

         3.3x 

         3.3x 

         4.2x 

Segmented sales

(in millions of Canadian dollars) (unaudited)

Q1 2026

Q4 2025

Q1 2025





Packaging Products

715

757

762

Tissue Papers

380

407

364

Inter-segment sales, Corporate, Recovery and Recycling activities  

30

33

28

Sales

1,125

1,197

1,154

Segmented operating income (loss)

(in millions of Canadian dollars) (unaudited)

Q1 2026

Q4 2025

Q1 2025





Packaging Products

88

90

60

Tissue Papers

20

14

24

Corporate, Recovery and Recycling activities  

(27)

(28)

(34)

Operating income

81

76

50

Segmented EBITDA (A)1

(in millions of Canadian dollars) (unaudited)

Q1 2026

Q4 2025

Q1 2025





Packaging Products

103

132

109

Tissue Papers

33

42

37

Corporate, Recovery and Recycling activities  

(18)

(19)

(21)

EBITDA (A)1

118

155

125

1 Please refer to the "Supplemental Information on Non-IFRS Accounting Standards Measures and Other Financial Measures" section for a complete reconciliation.

Analysis of results for the three-month period ended March 31, 2026 (compared to the same period last year)

The Corporation's first quarter sales of $1,125 million decreased by $29 million compared with the same period last year. This decrease reflects consolidated net benefits of $18 million from higher selling prices and a favourable sales mix of $21 million. However, these factors were more than offset by an unfavourable foreign exchange rate of $33 million and by a $35 million impact from lower volumes, mainly in the Packaging Products segment, reflecting the impact of business closures and dispositions.

The first quarter EBITDA (A)1 totaled $118 million, a decrease of $7 million, or 6%, from the $125 million generated in the same period last year. This decrease was driven by higher logistics, production and energy costs across the Corporation's businesses, and lower volumes in the Packaging Products segment. These impacts were partially offset by the benefits from higher selling prices and lower raw material costs.

The main specific items, before income taxes, that impacted our first quarter of 2026 operating income and/or net earnings were:

  • $8 million of impairment on a building and equipment related to a previously closed plant in the United States (operating income and net earnings);
  • $49 million of gains related to the sale of a business and some assets in Canada (operating income and net earnings);
  • $3 million of restructuring costs related to plants closure in Canada and in the United States and corporate organizational changes (operating income and net earnings);
  • $4 million loss on financial instruments (operating income and net earnings).

For the three-month period ended March 31, 2026, the Corporation posted net earnings of $39 million, or $0.38 per common share, compared to net earnings of $7 million, or $0.07 per common share, in the same period of 2025. On an adjusted basis1, the Corporation posted net earnings of $7 million in the first quarter of 2026, or $0.07 per common share, compared to net earnings of $13 million, or $0.13 per common share, in the same period of 2025.

1 Please refer to the "Supplemental Information on Non-IFRS Accounting Standards Measures and Other Financial Measures" section for a complete reconciliation.

Dividend on common shares and normal course issuer bid

The Board of Directors of Cascades declared a quarterly dividend of $0.12 per common share to be paid on June 4, 2026 to shareholders of record at the close of business on May 21, 2026. This dividend is an "eligible dividend" as per the Income Tax Act (R.C.S. (1985), Canada). During the first quarter of 2026, Cascades purchased no common shares for cancellation.

2026 First Quarter Results Conference Call Details

Management will discuss the 2026 first quarter financial results during a conference call today at 9:00 a.m. ET. The call can be accessed by dialing 1-800-990-4777 (international 1-289-819-1299). The conference call, including the investor presentation, will be broadcast live on the Cascades website (www.cascades.com) under the "Investors" section. A replay of the call will be available on the Cascades website and may also be accessed by phone until June 7, 2026 by dialing 1-888-660-6345 (international 1-289-819-1450), access code 49689 #.

Founded in 1964, Cascades offers sustainable, innovative and value-added packaging, hygiene and recovery solutions. The company employs approximately 8,800 women and men across a network of 61 operating facilities, including 17 Recovery and Recycling facilities which are part of Corporate Activities and joint ventures managed by the Corporation, in North America. Driven by its participative management, half a century of experience in recycling, and continuous research and development efforts, Cascades continues to provide innovative products that customers have come to rely on, while contributing to the well-being of people, communities and the entire planet. Cascades' shares trade on the Toronto Stock Exchange under the ticker symbol CAS. Certain statements in this release, including statements regarding future results and performance, are forward-looking statements based on current expectations. The accuracy of such statements is subject to a number of risks, uncertainties and assumptions that may cause actual results to differ materially from those projected, including, but not limited to, the effect of general economic conditions, decreases in demand for the Corporation's products, increases in raw material costs, fluctuations in selling prices and adverse changes in general market and industry conditions and other factors.

CONSOLIDATED BALANCE SHEETS

(in millions of Canadian dollars) (unaudited)

March 31,
2026

December 31,
2025

Assets



Current assets



Cash and cash equivalents

85

48

Accounts receivable

444

426

Current income tax assets

12

12

Inventories

681

661

Current portion of financial assets

4

4


1,226

1,151

Long-term assets



Investments in associates and joint ventures

68

66

Property, plant and equipment

2,633

2,649

Intangible assets with finite useful life

30

30

Financial assets

3

5

Other assets

107

107

Deferred income tax assets

180

174

Goodwill and other intangible assets with indefinite useful life

495

491


4,742

4,673

Liabilities and Equity



Current liabilities



Trade and other payables

685

697

Current income tax liabilities

4

4

Current portion of long-term debt

78

70

Current portion of provisions for charges

7

8

Current portion of financial liabilities and other liabilities

28

28


802

807

Long-term liabilities



Long-term debt

1,908

1,874

Provisions for charges

58

58

Financial liabilities

11

8

Other liabilities

69

74

Deferred income tax liabilities

101

97


2,949

2,918

Equity



Capital stock

619

619

Contributed surplus

18

17

Retained earnings

1,069

1,042

Accumulated other comprehensive income

51

43

Equity attributable to Shareholders

1,757

1,721

Non-controlling interests

36

34

Total equity

1,793

1,755


4,742

4,673

CONSOLIDATED STATEMENTS OF EARNINGS


For the 3-month periods
ended
 March 31,

(in millions of Canadian dollars, except per common share amounts and number of common shares) (unaudited)  

2026

2025

Sales

1,125

1,154




Supply chain and logistics

679

679

Wages and employee benefits expenses

266

280

Depreciation and amortization

71

69

Maintenance and repair

60

64

Other operational costs

2

6

Impairment charges

8

1

Other loss (gain)

(49)

4

Restructuring costs

3

5

Loss (gain) on derivative financial instruments

4

(4)

Operating income

81

50

Financing expenses

31

36

Share of results of associates and joint ventures

(2)

(3)

Earnings before income taxes

52

17

Provision for income taxes

8

5

Net earnings including non-controlling interests for the period

44

12

Net earnings attributable to non-controlling interests

5

5

Net earnings attributable to Shareholders for the period

39

7

Net earnings per common share



Basic

$0.38

$0.07

Diluted

$0.38

$0.07

Weighted average basic number of common shares outstanding

101,283,722

100,993,811

Weighted average number of diluted common shares

102,033,598

101,421,656

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME


For the 3-month periods
ended
 March 31,

(in millions of Canadian dollars) (unaudited)

2026

2025

Net earnings including non-controlling interests for the period

44

12

Other comprehensive income (loss)



Items that may be reclassified subsequently to earnings



Translation adjustments



Change in foreign currency translation of foreign subsidiaries

15

(41)

Change in foreign currency translation related to net investment hedging activities

(7)

40

Recovery of income taxes

1


9

(1)

Items that are not released to earnings



Actuarial loss on employee future benefits

(1)

Other comprehensive income (loss)

9

(2)

Comprehensive income including non-controlling interests for the period

53

10

Comprehensive income attributable to non-controlling interests for the period

6

5

Comprehensive income attributable to Shareholders for the period

47

5

CONSOLIDATED STATEMENTS OF EQUITY


For the 3-month period ended March 31, 2026

(in millions of Canadian dollars) (unaudited)

CAPITAL STOCK

CONTRIBUTED
SURPLUS

RETAINED
EARNINGS

ACCUMULATED
OTHER
COMPREHENSIVE
INCOME

TOTAL EQUITY
ATTRIBUTABLE TO
SHAREHOLDERS

NON-
CONTROLLING
INTERESTS

TOTAL EQUITY

Balance - Beginning of period

619

17

1,042

43

1,721

34

1,755

Comprehensive income








Net earnings

39

39

5

44

Other comprehensive income

8

8

1

9


39

8

47

6

53

Dividends

(12)

(12)

(4)

(16)

Stock options expense

1

1

1

Balance - End of period

619

18

1,069

51

1,757

36

1,793










For the 3-month period ended March 31, 2025

(in millions of Canadian dollars) (unaudited)

CAPITAL STOCK

CONTRIBUTED
SURPLUS

RETAINED
EARNINGS

ACCUMULATED
OTHER
COMPREHENSIVE
INCOME

TOTAL EQUITY
ATTRIBUTABLE TO
SHAREHOLDERS

NON-
CONTROLLING
INTERESTS

TOTAL EQUITY

Balance - Beginning of period

616

16

1,019

73

1,724

47

1,771

Comprehensive income (loss)








Net earnings

7

7

5

12

Other comprehensive income (loss)

(1)

(1)

(2)

(2)


6

(1)

5

5

10

Dividends

(12)

(12)

(3)

(15)

Issuance of common shares upon exercise of stock options

1

1

1

Balance - End of period

617

16

1,013

72

1,718

49

1,767

CONSOLIDATED STATEMENTS OF CASH FLOWS


For the 3-month periods
ended
 March 31,

(in millions of Canadian dollars) (unaudited)

2026

2025

Operating activities



Net earnings attributable to Shareholders for the period

39

7

Adjustments for:



Financing expenses

31

36

Depreciation and amortization

71

69

Impairment charges

8

1

Other loss (gain)

(49)

4

Restructuring costs

3

5

Loss (gain) on derivative financial instruments

4

(4)

Provision for income taxes

8

5

Share of results of associates and joint ventures

(2)

(3)

Net earnings attributable to non-controlling interests

5

5

Net financing expenses paid

(52)

(49)

Net income taxes paid

(4)

(2)

Payments, net of provisions, for charges and other liabilities, and other non-cash items

(6)

(29)


56

45

Changes in non-cash working capital components

(38)

(97)


18

(52)

Investing activities



Payments for property, plant and equipment

(28)

(36)

Proceeds from disposals of property, plant and equipment

31

Change in intangible and other assets

(1)

1

Proceeds from business disposal

60


62

(35)

Financing activities



Bank loans and advances

(6)

Change in credit facilities

(2)

303

Change in credit facilities without recourse to the Corporation

(4)

1

Repurchase of unsecured senior notes

(175)

Payments of other long-term debt, including lease obligations (2026 - $21 million for the 3-month period; 2025 -
   $18 million for the 3-month period)

(21)

(19)

Issuance of common shares upon exercise of stock options

1

Dividends paid to non-controlling interests

(4)

(3)

Dividends paid to the Corporation's Shareholders

(12)

(12)


(43)

90

Net change in cash and cash equivalents during the period

37

3

Currency translation on cash and cash equivalents

(1)

Cash and cash equivalents - Beginning of the period

48

27

Cash and cash equivalents - End of the period

85

29

SEGMENTED INFORMATION

The Corporation's operations are managed in two segments: Packaging Products and Tissue Papers. The accounting policies of the reportable segments are the same as the Corporation's accounting policies described in the most recent Audited Consolidated Financial Statements for the year ended December 31, 2025.

The Corporation's operating segments are reported in a manner consistent with the internal reporting provided to the chief operating decision-maker (CODM). The Chief Executive Officer has authority for resource allocation and management of the Corporation's performance and is therefore the CODM. The CODM assesses the performance of each reportable segment based on sales and earnings before interest, taxes, depreciation and amortization, adjusted to exclude specific items (EBITDA (A)). The CODM considers EBITDA (A) to be the best performance measure of the Corporation's activities.

Sales for each segment are prepared on the same basis as those of the Corporation. Inter-segment operations are recorded on the same basis as sales to third parties, which are at fair market value.

EBITDA (A) does not have a standardized meaning under IFRS Accounting Standards; accordingly, it may not be comparable to similarly named measures used by other companies. Investors should not view EBITDA (A) as an alternative measure to, for example, net earnings, or as a measure of operating results, which are IFRS Accounting Standards measures.

Sales by business segment are shown in the following table:


SALES

For the 3-month periods ended March 31                                                
   (in millions of Canadian dollars) (unaudited)

2026

2025

Total

Inter-segment

External

Total

Inter-segment

External

Packaging Products

715

(6)

709

762

(13)

749

Tissue Papers

380

380

364

364

Corporate, Recovery and Recycling activities

62

(26)

36

73

(32)

41


1,157

(32)

1,125

1,199

(45)

1,154

EBITDA (A) by business segment is reconciled to the IFRS Accounting Standards measure, namely operating income (loss), and is shown in the following table:


For the 3-month period ended March 31, 2026

(in millions of Canadian dollars) (unaudited)

Packaging
Products

Tissue Papers

Corporate,
Recovery and
Recycling
activities

Consolidated

Operating income (loss)

88

20

(27)

81

Depreciation and amortization

49

13

9

71

Impairment charges

8

8

Other gain

(47)

(2)

(49)

Restructuring costs

1

2

3

Loss on derivative financial instruments

4

4

EBITDA (A)

103

33

(18)

118

Supply chain and logistics and Wage and employee benefits expenses included in operating income (loss)

568

327

50

945




For the 3-month period ended March 31, 2025

(in millions of Canadian dollars) (unaudited)

Packaging
Products

Tissue Papers

Corporate,
Recovery and
Recycling
activities

Consolidated

Operating income (loss)

60

24

(34)

50

Depreciation and amortization

46

13

10

69

Impairment charges

1

1

Other loss

4

4

Restructuring costs

1

4

5

Gain on derivative financial instruments

(2)

(2)

(4)

EBITDA (A)

109

37

(21)

125

Supply chain and logistics and Wage and employee benefits expenses included in operating income (loss)

603

304

52

959

Payments for property, plant and equipment by business segment are shown in the following table:


PAYMENTS FOR PROPERTY, PLANT AND
EQUIPMENT


For the 3-month periods
ended
 March 31,

(in millions of Canadian dollars) (unaudited)

2026

2025

Packaging Products

46

34

Tissue Papers

7

8

Corporate, Recovery and Recycling activities

16

6

Total acquisitions

69

48

Right-of-use assets acquisitions and provisions (non-cash)

(45)

(24)


24

24

Acquisitions for property, plant and equipment included in "Trade and other payables"



Beginning of the period

17

32

End of the period

(13)

(20)

Payments for property, plant and equipment

28

36

Proceeds from disposals of property, plant and equipment

(31)

Payments for property, plant and equipment net of proceeds from disposals

(3)

36

SUPPLEMENTAL INFORMATION ON NON-IFRS ACCOUNTING STANDARDS MEASURES AND OTHER FINANCIAL MEASURES

SPECIFIC ITEMS

The Corporation incurs some specific items that adversely or positively affect its operating results. We believe it is useful for readers to be aware of these items as they provide additional information to measure performance, compare the Corporation's results between periods, and assess operating results and liquidity, notwithstanding these specific items. Management believes these specific items are not necessarily reflective of the Corporation's underlying business operations in measuring and comparing its performance and analyzing future trends. Our definition of specific items may differ from that of other corporations and some of these items may arise in the future and may reduce the Corporation's available cash.

They include, but are not limited to, charges for (reversals of) impairment of assets, restructuring gains or costs, loss on refinancing and repurchase of long-term debt, some deferred tax asset provisions or reversals, premiums paid on repurchase of long-term debt, gains or losses on the acquisition or sale of a business unit, gains or losses on the share of results of associates and joint ventures, unrealized and realized gains or losses on derivative financial instruments that do not qualify for hedge accounting, unrealized gains or losses on interest rate hedge instruments and option fair value revaluation, foreign exchange gains or losses on long-term debt and financial instruments, fair value revaluation gains or losses on investments, specific items of discontinued operations and other significant items of an unusual, non-cash or non-recurring nature.

RECONCILIATION AND USES OF NON-IFRS ACCOUNTING STANDARDS MEASURES AND OTHER FINANCIAL MEASURES

To provide more information for evaluating the Corporation's performance, the financial information included in this analysis contains certain data that are not performance measures under IFRS Accounting Standards ("non-IFRS Accounting Standards measures"), which are also calculated on an adjusted basis to exclude specific items. We believe that providing certain key performance and capital measures, as well as non-IFRS Accounting Standards measures, is useful to both Management and investors, as they provide additional information to measure the performance and financial position of the Corporation. This also increases the transparency and clarity of the financial information. The following non-IFRS Accounting Standards measures and other financial measures are used in our financial disclosures:

Non-IFRS Accounting Standards measures

  • Adjusted earnings before interest, taxes, depreciation and amortization or EBITDA (A): represents the operating income (as published in the Consolidated Statements of Earnings (Loss) of the Consolidated Financial Statements) before depreciation and amortization excluding specific items. Measure used to assess recurring operating performance and the contribution of each segment on a comparable basis.
  • Adjusted net earnings: Measure used to assess the Corporation's consolidated financial performance on a comparable basis.
  • Adjusted cash flow: Measure used to assess the Corporation's capacity to generate cash flows to meet financial obligations and/or discretionary items such as share repurchases, dividend increases and strategic investments.
  • Free cash flow: Measure used to calculate the excess cash the Corporation generates by subtracting capital expenditures (excluding strategic projects) from the EBITDA (A).
  • Working capital: Measure used to assess the short-term liquidity of the Corporation.

Other financial measures

  • Total debt: Measure used to calculate all the Corporation's debt, including long-term debt and bank loans. Often put in relation to equity to calculate the debt-to-equity ratio.
  • Net debt: Measure used to calculate the Corporation's total debt less cash and cash equivalents. Often put in relation to EBITDA (A) to calculate the net debt to EBITDA (A) ratio.

Non-IFRS Accounting Standards ratios

  • Net debt to EBITDA (A) ratio: Ratio used to assess the Corporation's ability to pay its debt and evaluate financial leverage.
  • EBITDA (A) margin: Ratio used to assess operating performance and the contribution of each segment on a comparable basis calculated as a percentage of sales.
  • Adjusted net earnings per common share: Ratio used to assess the Corporation's consolidated financial performance on a comparable basis.
  • Ratio of net debt / (total equity and net debt): Ratio used to evaluate the Corporation's financial leverage and the risk to Shareholders.
  • Working capital as a percentage of sales: Ratio used to assess the Corporation's operating liquidity performance.
  • Adjusted cash flow per common share: Ratio used to assess the Corporation's financial flexibility.
  • Free cash flow ratio: Ratio used to measure the liquidity and efficiency of how much more cash the Corporation generates than it uses to run the business by subtracting capital expenditures (excluding strategic projects) from the EBITDA (A) calculated as a percentage of sales.

Non-IFRS Accounting Standards measures and other financial measures are mainly derived from the consolidated financial statements, but do not have the meanings prescribed by IFRS Accounting Standards. These measures have limitations as an analytical tool and should not be considered on their own or as a substitute for an analysis of our results as reported under IFRS Accounting Standards. In addition, our definitions of non-IFRS Accounting Standards measures and other financial measures may differ from those of other corporations. Any such modification or reformulation may be significant.

The Corporation's operations are managed in two segments: Packaging Products and Tissue Papers.

The CODM assesses the performance of each reportable segment based on sales and earnings before interest, taxes, depreciation and amortization, adjusted to exclude specific items (EBITDA (A)1). The CODM considers EBITDA (A)1 to be the best performance measure of the Corporation's activities.

EBITDA (A)1 by business segment is reconciled to the IFRS Accounting Standards measure, namely operating income (loss), and is shown in the following table:


Q1 2026

(in millions of Canadian dollars) (unaudited)

Packaging
Products

Tissue Papers

Corporate,
Recovery and
Recycling
activities

Consolidated

Operating income (loss)

88

20

(27)

81

Depreciation and amortization

49

13

9

71

Impairment charges

8

8

Other gain

(47)

(2)

(49)

Restructuring costs

1

2

3

Loss on derivative financial instruments

4

4

EBITDA (A)1

103

33

(18)

118

Supply chain and logistics and Wage and employee benefits expenses included in operating income (loss)

568

327

50

945




Q4 2025

(in millions of Canadian dollars) (unaudited)

Packaging
Products

Tissue Papers

Corporate,
Recovery and
Recycling
activities

Consolidated

Operating income (loss)

90

14

(28)

76

Depreciation and amortization

49

16

7

72

Impairment charges

11

12

2

25

Other gain

(21)

(21)

Restructuring costs

3

1

4

Gain on derivative financial instruments

(1)

(1)

EBITDA (A)1

132

42

(19)

155

Supply chain and logistics and Wage and employee benefits expenses included in operating income (loss)

579

342

54

975



1 Please refer to the "Supplemental Information on Non-IFRS Accounting Standards Measures and Other Financial Measures" section for a complete reconciliation.




Q1 2025

(in millions of Canadian dollars) (unaudited)

Packaging
Products

Tissue Papers

Corporate,
Recovery and
Recycling
activities

Consolidated

Operating income (loss)

60

24

(34)

50

Depreciation and amortization

46

13

10

69

Impairment charges

1

1

Other loss

4

4

Restructuring costs

1

4

5

Gain on derivative financial instruments

(2)

(2)

(4)

EBITDA (A)1

109

37

(21)

125

Supply chain and logistics and Wage and employee benefits expenses included in operating income (loss)

603

304

52

959

The following table reconciles net earnings and net earnings per common share, as reported, with adjusted net earnings1 and adjusted net earnings per common share1:

(in millions of Canadian dollars, except per common share amounts and number of
   common shares) (unaudited)  

NET EARNINGS


NET EARNINGS

PER COMMON SHARE2


Q1 2026

Q4 2025

Q1 2025


Q1 2026

Q4 2025

Q1 2025

As reported

39

37

7


$0.38

$0.37

$0.07

Specific items:








Impairment charges

8

25

1


$0.06

$0.19

$0.01

Other loss (gain)

(49)

(21)

4


($0.42)

($0.18)

$0.03

Restructuring costs

3

4

5


$0.02

$0.03

$0.04

Loss (gain) on derivative financial instruments

4

(1)

(4)


$0.03

($0.01)

($0.03)

Tax effect on specific items, other tax adjustments and attributable to non-controlling interest2

2

(4)


$0.01


(32)

3

6


($0.31)

$0.03

$0.06

Adjusted1

7

40

13


$0.07

$0.40

$0.13

Weighted average basic number of common shares outstanding





101,283,722

101,261,141

100,993,811

The following table reconciles cash flow from operating activities with EBITDA (A)1:

(in millions of Canadian dollars) (unaudited)

Q1 2026

Q4 2025

Q1 2025

Cash flow from operating activities

18

183

(52)

Changes in non-cash working capital components

38

(33)

97

Net income taxes paid

4

1

2

Net financing expenses paid

52

16

49

Payments, net of provisions, for charges and other liabilities, and non-cash items, net of dividends received  

6

(12)

29

EBITDA (A)1

118

155

125

1 Please refer to the "Supplemental Information on Non-IFRS Accounting Standards Measures and Other Financial Measures" section for a complete reconciliation.

2 Specific amounts per common share are calculated on an after-tax basis and are net of the portion attributable to non-controlling interests. Per share amounts in line item ''Tax effect on specific items, other tax adjustments and attributable to non-controlling interests'' only include the effect of tax adjustments. Please refer to the "Provision for income taxes" section for more details.

The following table reconciles cash flow from operating activities with cash flow from operating activities (excluding changes in non-cash working capital components) and adjusted cash flow from operating activities1. It also reconciles adjusted cash flow from operating activities1 to adjusted cash flow generated (used)1, which is also calculated on a per common share basis:

(in millions of Canadian dollars, except per common share amounts or otherwise noted) (unaudited)

Q1 2026

Q4 2025

Q1 2025

Cash flow from operating activities

18

183

(52)

Changes in non-cash working capital components

38

(33)

97

Cash flow from operating activities (excluding changes in non-cash working capital components)  

56

150

45

Restructuring costs paid

3

15

17

Adjusted cash flow from operating activities1

59

165

62

Payments for property, plant and equipment

(28)

(42)

(36)

Change in intangible and other assets

(1)

1

Lease obligation payments

(21)

(19)

(18)


9

104

9

Dividends paid to non-controlling interests

(4)

(4)

(3)

Dividends paid to the Corporation's Shareholders and to non-controlling interests

(12)

(13)

(12)

Adjusted cash flow generated (used)1

(7)

87

(6)

Adjusted cash flow generated (used) per common share1

 (in Canadian dollars)

($0.07)

$0.86

($0.06)

Weighted average basic number of common shares outstanding

101,283,722

101,261,141

100,993,811

The following table reconciles total debt1 and net debt1 with the ratio of net debt to adjusted earnings before interest, taxes, depreciation and amortization (EBITDA (A))1:

(in millions of Canadian dollars) (unaudited)

March 31,

2026

December 31,

 2025

March 31,

2025

Long-term debt

1,908

1,874

1,873

Current portion of unsecured senior notes

296

Current portion of long-term debt

78

70

72

Bank loans and advances

4

Total debt1

1,986

1,944

2,245

Less: Cash and cash equivalents

(85)

(48)

(29)

Net debt1 as reported

1,901

1,896

2,216

Last twelve months EBITDA (A)1

569

576

523

Net debt / EBITDA (A) ratio1

         3.3x 

         3.3x 

         4.2x 

1 Please refer to the "Supplemental Information on Non-IFRS Accounting Standards Measures and Other Financial Measures" section for a complete reconciliation.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/cascades-reports-results-for-the-first-quarter-of-2026-302764694.html

SOURCE Cascades Inc.